

May 12, 2025

To
The Corporate Relations Department
BSE Limited
Phiroz Jeejeebhoy Towers, 25th Floor,
Dalal Street,
Mumbai- 400001
Scrip Code - 543308
ISIN: INE967H01025

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
Symbol - KIMS
ISIN: INE967H01025

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on May 12, 2025 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Further to our intimations dated May 02, 2025, the Board of Directors, at its meeting held today, has approved the Audited (Standalone and Consolidated) financial results of the Company for the quarter and financial year ended 31st March 2025.

As required by the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose/furnish the following particulars:

1. Financials & Audit Reports:

- i. Audited standalone financial results of the Company for the quarter and financial year ended 31st March 2025, along with the Audit Report on the standalone financial statement.
- ii. Audited consolidated financial results of the Company for the quarter and financial year ended 31st March 2025, along with the Audit Report on the consolidated financial statement.
- iii. The report of S.R. Batliboi & Associates LLP, Statutory Auditors of the Company, with an unmodified opinion with respect to the Audited Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2025.

The audited financial results and audit reports (standalone & consolidated) along with the annexures therewith are enclosed as "**Annexure-1**".

2. **Appointment of Secretarial Auditors:** The Board has approved the appointment of M/s. IKR & Associates, Company Secretaries (a peer-reviewed firm) as Secretarial Auditors of the Company for five consecutive years with effect from April 01, 2025 until March 31, 2030, subject to the approval of shareholders of the Company in the ensuing Annual General Meeting for the period of 5 years till FY 30.

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as "**Annexure-2**".

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

3. **Appointment of Cost Auditors:** Pursuant to the recommendation made by the Audit Committee, Board has appointed M/s. Sagar & Associates, Cost Accountants to audit the cost records of the Company for FY 2025-26 and also recommended their remuneration for the approval of members in the ensuing AGM.

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as "**Annexure-3**"

4. **Re-appointment of Mrs. Y. Prameela Rani (DIN: 03270909) as Independent Director (Non-Executive & Independent) for second term of 5 years:** Pursuant to the recommendation of Nomination & Remuneration committee, the Board has re-appointed Mrs. Y. Prameela Rani as an Independent Director for the further period of 5 years w.e.f 19.05.2025.

Mrs. Y. Prameela Rani has confirmed that she meets the criteria of 'Independence' Section 149 of Companies Act, 2013 and Regulation 16 of SEBI LODR regulations and further she has confirmed that she has not been debarred from holding the office as Independent Director of the Company by virtue of any order passed by the SEBI.

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as "**Annexure-4**".

5. **Annual General Meeting (AGM):** The 23rd Annual General Meeting of the Company will be held on Friday, 29th August 2025.

Further, the financial results are also available on the website of the Company at [https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI \(LODR\) Regulations, 2015/ Financial Information/ Financial Result](https://www.kimshospitals.com/investors/Disclosures_under_Regulation_46_of_SEBI_(LODR)_Regulations,_2015/_Financial_Information/_Financial_Result) and on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. www.bseindia.com and www.nseindia.com, respectively.

Further, the financial results will also be published in the newspaper as per the requirement and in the format prescribed under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Board Meeting Commenced at : 02.00 P.M.

Board Meeting Concluded at : 07: 15 P.M

This is for your information and records.

Thanking you,

For Krishna Institute of Medical Sciences Limited

Dr. Bhaskara Rao Bollineni
Managing Director & Chairman
DIN: 00008985

Enclosed: As above

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

THE SKYVIEW 10
18th Floor, "NORTH LOBBY"
Survey No. 83/1, Raidurgam
Hyderabad - 500 032, India
Tel : +91 40 6141 6000

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
**The Board of Directors of
Krishna Institute of Medical Sciences Limited**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter ended March 31, 2025 and for the year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income/(loss) and other financial information of the Company for the quarter ended March 31, 2025 and for the year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income/(loss) of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004

Navneet Rai

per Navneet Rai Kabra
Partner

Membership No.: 102328

UDIN: 25102328BMOP2L3150

Place: Hyderabad

Date: May 12, 2025




Statement of Audited Standalone Financial Results for the quarter and year ended 31 March 2025

(Rupees in millions)

		Quarter ended			Year ended	
		31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
		(Audited) (refer note 2)	(Unaudited)	(Audited) (refer note 2)	(Audited)	(Audited)
1	Income					
	(a) Revenue from operations	3,459	3,475	3,048	13,841	12,221
	(b) Other income	242	206	39	567	182
	Total Income	3,701	3,681	3,087	14,408	12,403
2	Expenses					
	(a) Purchase of medical consumables, drugs and surgical instruments	707	752	594	2,795	2,536
	(b) (Increase)/decrease in inventories of medical consumables, drugs and surgical instruments	6	(57)	13	(42)	(29)
	(c) Employee benefits expense	582	571	561	2,364	2,196
	(d) Other expenses	1,077	1,180	1,017	4,559	3,901
	(e) Finance costs	81	67	23	232	36
	(f) Depreciation and amortisation expenses	151	149	204	577	581
	Total Expenses	2,604	2,662	2,412	10,485	9,221
3	Profit before tax and exceptional items (1-2)	1,097	1,019	675	3,923	3,182
4	Exceptional items	108	-	-	108	-
5	Profit before tax (3+4)	1,205	1,019	675	4,031	3,182
6	Tax expense					
	(a) Current tax	204	236	180	951	817
	(b) Deferred tax charge	66	18	13	51	12
	Total tax expenses	270	254	193	1,002	829
7	Profit for the period/year (5-6)	935	765	482	3,029	2,353
8	Other comprehensive (loss)/income for the period/year					
	Items that will not be reclassified subsequently to statement of profit and loss					
	- Re-measurement gain/(loss) on defined benefit plans	10	(9)	(5)	(18)	3
	- Income tax effect	(2)	2	1	5	(1)
	Other comprehensive income/(loss), net of tax	8	(7)	(4)	(13)	2
9	Total comprehensive income for the period/year (7+8)	943	758	478	3,016	2,355
10	Paid up equity share capital (face value of Rs.2 each)				800	800
11	Other Equity				20,880	17,864
12	Earnings per share (of Rs.2 each) : (not annualised for the quarter ended)					
	(a) Basic (Rs.)*	2.34	1.91	1.20	7.57	5.88
	(b) Diluted (Rs.)*	2.34	1.91	1.20	7.57	5.88

*The equity shares of the Company of Rs. 10/- each has been sub-divided into 5 equity shares of Rs. 2/- each w.e.f. September 13, 2024, accordingly EPS has been restated for all the periods.




[Handwritten signature]

Notes:

- 1 The above statement of audited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company"), have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12 May 2025. The Statutory Auditors have expressed an unmodified opinion on the standalone financial results.
- 2 The standalone figures for the quarter ended 31 March 2025 and quarter ended 31 March 2024 are the balancing figures between the audited standalone figures in respect of the full financial year ended 31 March 2025 and 31 March 2024, respectively and the published year to date standalone figures up to third quarter 31 December 2024 and 31 December 2023, respectively which were subjected to a limited review.
- 3 During the quarter, the Company has entered into Operations and Management Agreements with entities in the healthcare sector to operate and manage their hospitals. The Company has also executed Call Option Agreements to acquire a majority equity stake in these entities at pre-agreed terms. The call options have been valued at Rs 108 Mn and the gain has been recognized as an exceptional item.
- 4 The Board of Directors, at their meeting held on June 28, 2024, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs. 10/- each into 5 equity shares of Rs. 2/- each), and the same has been approved by the shareholders in the Annual General Meeting of the Company held on August 29, 2024. The Company fixed the "record date" of September 13, 2024. Accordingly, equity shares of the Company of Rs. 10/- have been sub-divided into 5 equity shares of Rs. 2/- each w.e.f. September 13, 2024 and earnings per equity share has been restated for all the periods.
- 5 During the year, the Company acquired 100% of the equity share capital of Chalasani Hospitals Private Limited (Queen's NRI Hospital) for a total cash consideration of Rs. 1,112 Mn, consisting of Rs. 277 Mn towards purchase of shares and Rs. 835 Mn towards purchase of hospital land and building. Consequently, Queen's NRI Hospital has become a wholly owned subsidiary.
- 6 The Audited Standalone Balance sheet and Audited Standalone Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- 7 The Company operates in one single reportable business segment- "Medical and Healthcare services".
- 8 The above Audited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

Hyderabad
12 May 2025



For and on behalf of the Board
Krishna Institute of Medical Sciences Limited




Dr. B. Bhaskara Rao
Managing Director
DIN: 00008985

Krishna Institute of Medical Sciences Limited
Corporate Identity number : L55101TG1973PLC040558
Registered office : I-8-31/I, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Audited Standalone Balance Sheet as at 31 March 2025

(Rupees in millions)

	Particulars	As at 31 March 2025 (Audited)	As at 31 March 2024 (Audited)
A	ASSETS		
1	Non-current Assets		
	Property, plant and equipment	7,238	6,265
	Capital work-in-progress	5,303	2,920
	Intangible assets	208	184
	Right-of-use assets	287	290
	Financial assets		
	(i) Investments	12,258	10,007
	(ii) Loans	2,761	958
	(iii) Other financial assets	278	100
	Non-current tax assets (net)	-	37
	Other non-current assets	564	193
	Total Non-current Assets - (1)	28,897	20,954
2	Current Assets		
	Inventories	263	221
	Financial assets		
	(i) Investments	-	616
	(ii) Trade receivables	1,874	1,487
	(iii) Cash and cash equivalents	261	205
	(iv) Bank balances other than (iii) above	34	-
	(v) Loans	70	92
	(vi) Other financial assets	304	235
	Other current assets	188	156
	Total Current Assets - (2)	2,994	3,012
3	Total Assets (3) = (1)+(2)	31,891	23,966
B	EQUITY AND LIABILITIES		
4	Equity		
	Equity share capital	800	800
	Other equity	20,880	17,864
	Total Equity - (4)	21,680	18,664
5	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	5,771	2,572
	(ii) Other financial liabilities	26	100
	Provisions	207	191
	Other non-current liabilities	228	-
	Deferred tax liabilities (net)	392	346
	Total Non-current liabilities - (5)	6,624	3,209
6	Current liabilities		
	Financial liabilities		
	(i) Borrowings	1,309	691
	(ii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	52	3
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	892	782
	(iii) Other financial liabilities	833	179
	Other current liabilities	346	336
	Provisions	139	102
	Current tax liabilities (net)	16	-
	Total Current liabilities - (6)	3,587	2,093
	Total Equity and Liabilities (7) = (4)+(5)+(6)	31,891	23,966



M. Anand

Krishna Institute of Medical Sciences Limited

Corporate Identity number : L55101TG1973PLC040558

Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India

Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Audited Standalone Cashflows for the year ended 31 March 2025

(Rupees in millions)

Particulars	For the year ended	
	31-Mar-25	31-Mar-24
	(Audited)	(Audited)
I. Cash flows from operating activities:		
Profit before tax for the year	4,031	3,182
Adjustments for operating activities:		
Depreciation and amortisation expense	577	581
Profit on sale of property, plant and equipment	(128)	(1)
Provision/(reversal) of expected credit loss for trade receivables (net of bad debts)	81	(27)
Guarantee commission income	(161)	(12)
Rental income	(1)	(1)
Interest income	(224)	(90)
Liabilities no longer required written back	-	(7)
Interest income on income tax refund	(4)	-
Gain on fair valuation of Call option (net)	(108)	-
Gain on Mutual funds	(29)	(3)
Finance costs	232	36
Operating cash flows before working capital changes	4,266	3,658
Adjustments for:		
Increase		
- in trade receivables	(468)	(261)
- in inventories	(42)	(29)
- in other financial assets and other assets	(110)	(152)
Increase in trade payables, other financial liabilities, provisions and other liabilities	188	261
Cash generated from operations	3,834	3,477
Income taxes paid, net of refunds	(898)	(853)
Net cash generated from operating activities (1)	2,936	2,624
II. Cash flows from investing activities		
Acquisition of property, plant and equipment and intangible assets	(3,517)	(3,209)
Proceeds from sale of property, plant and equipment	459	5
Investment in subsidiaries	(2,202)	(2,143)
Investment in mutual funds	(1,895)	(1,955)
Proceeds from sale of mutual funds	2,540	1,753
Loans given to subsidiaries	(2,928)	(318)
Loans repaid by subsidiaries	1,147	145
Redemption of bank deposits (having original maturity of more than three months)	12	20
Investment in bank deposits (having original maturity of more than three months)	(46)	(2)
Rental income received	1	1
Interest received	163	17
Net cash flows used in investing activities (2)	(6,266)	(5,686)
III. Cash flows from financing activities		
Proceeds from long-term borrowings	3,871	2,613
Repayment of long-term borrowings	(219)	-(42)
Proceeds from short-term borrowings (net)	165	650
Payment of lease obligations	-	(290)
Interest paid	(431)	(45)
Net cash flows generated from financing activities (3)	3,386	2,886
Net increase/(decrease) in cash and cash equivalents (1+2+3)	56	(176)
Cash and cash equivalents at the beginning of the year	205	381
Cash and cash equivalents at the end of the year	261	205
Components of cash and cash equivalents		
Cash on hand	14	10
Balances with banks		
- On current accounts	247	195
Total	261	205



M. Anand

Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Krishna Institute of Medical Sciences Limited

Report on the audit of the Consolidated Financial Results**Opinion**

We have audited the accompanying statement of quarterly and year to date consolidated financial results of Krishna Institute of Medical Sciences Limited ("Holding Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended March 31, 2025 and for the year ended March 31, 2025 ("Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements/ financial results/financial information of the subsidiaries and associate, the Statement:

- i. includes the results of the following entities;

S.No.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Hospital Bengaluru Private Limited	Subsidiary
10	Sarvejana Healthcare Private Limited**	Subsidiary
11	SPANV Medisearch Lifesciences Private Limited	Subsidiary
12	KIMS Manavata Hospitals Private Limited	Subsidiary
13	Meda Institute of Podiatry Private Limited *	Subsidiary
14	Chalasanani Hospitals Private Limited *	Subsidiary
15	Kondapur Healthcare Limited (Formerly known as RVM Healthcare Limited)	Associate

*Became a subsidiary during the current year

** Rajyalakshmi Healthcare Private Limited merged with Sarvejana Healthcare Private Limited (parent company) during the current year with effect from April 1, 2024

- ii. are presented in accordance with the requirements of the Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income/(loss) and other financial information of the Group for the quarter ended March 31, 2025 and for the year ended March 31, 2025.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended (“the Act”). Our responsibilities under those Standards are further described in the “Auditor’s Responsibilities for the Audit of the Consolidated Financial Results” section of our report. We are independent of the Group and its associate in accordance with the ‘Code of Ethics’ issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in “Other Matter” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management’s Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group including its associate in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of their respective companies and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group and of its associate are responsible for assessing the ability of their respective companies to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of its associate are also responsible for overseeing the financial reporting process of their respective companies.

Auditor’s Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group and its associate of which we are the independent auditors to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Master Circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

Other Matter

The accompanying Statement includes the audited financial results/statements and other financial information, in respect of:

- Four subsidiaries, whose financial results/statements include total assets of Rs. 4,752 million as at March 31, 2025, total revenues of Rs. 470 million and Rs. 953 million, total net loss after tax of Rs. 164 million and Rs. 230 million, total comprehensive loss of Rs. 164 million and Rs. 230 million, for the quarter and the year ended on that date respectively, and net cash inflows of Rs. 52 million for the year ended March 31, 2025, as considered in the Statement which have been audited by their respective independent auditors.
- An associate, whose financial results/statements include Group's share of net loss of Rs. Nil million and Rs. Nil million and Group's share of total comprehensive loss of Rs. Nil million and Rs. Nil million for the quarter and for the year ended March 31, 2025 respectively, as considered in the Statement whose financial results/financial statements, other financial information have been audited by their respective independent auditors.

The independent auditor's report on the financial statements/financial results/financial information of these entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associate is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004

Navneet Rai

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 25102328BMOPZMT188

Place: Hyderabad

Date: May 12, 2025




Statement of Audited Consolidated Financial Results for the quarter and year ended 31 March 2025

(Rupees in millions)

	Quarter Ended			Year ended	
	31-Mar-25	31-Dec-24	31-Mar-24	31-Mar-25	31-Mar-24
	(Audited) (Refer note 2)	(Unaudited)	(Audited) (Refer note 2)	(Audited)	(Audited)
1 Income					
(a) Revenue from operations	7,969	7,724	6,338	30,351	24,982
(b) Other income	45	178	38	319	161
Total Income	8,014	7,902	6,376	30,670	25,143
2 Expenses					
(a) Purchase of medical consumables, drugs and surgical instruments	1,692	1,698	1,352	6,404	5,369
(b) Increase in inventories of medical consumables, drugs and surgical instruments	(21)	(80)	(9)	(135)	(65)
(c) Employee benefits expense	1,341	1,275	1,085	4,995	4,224
(d) Other expenses	2,977	2,959	2,320	11,258	9,082
(e) Finance costs	267	257	164	903	470
(f) Depreciation and amortisation expenses	526	447	463	1,772	1,465
Total Expenses	6,782	6,556	5,375	25,197	20,545
3 Profit before share of loss from associate (1-2)	1,232	1,346	1,001	5,473	4,598
4 Share of loss from associate, net of tax	-	-	(1)	-	(3)
5 Profit before tax and exceptional items (3+4)	1,232	1,346	1,000	5,473	4,595
6 Exceptional items	108	-	-	108	-
7 Profit before tax (5+6)	1,340	1,346	1,000	5,581	4,595
8 Tax expense					
(a) Current tax	357	353	262	1,495	1,162
(b) Deferred tax charge/(credit)	(78)	68	23	(62)	74
Total tax expenses (8)	279	421	285	1,433	1,236
9 Profit for the period/year (7-8)	1,061	925	715	4,148	3,359
Attributable to:					
Owners of the company	1,018	887	655	3,845	3,100
Non controlling interests	43	38	60	303	259
10 Other comprehensive (loss)/ income for the period/year					
items that will not be reclassified subsequently to statement of profit and loss					
- Re-measurement (loss)/gain on defined benefit plans	11	(12)	(4)	(31)	4
- Income tax effect	(3)	3	1	8	(1)
Other comprehensive (loss)/ income, net of tax	8	(9)	(3)	(23)	3
Attributable to:					
Owners of the company	7	(7)	(3)	(20)	2
Non controlling interests	1	(2)	-	(3)	1
11 Total comprehensive income (9+10)					
Owners of the company	1,025	880	652	3,825	3,102
Non controlling interests	44	36	60	300	260
Total comprehensive income for the period/year	1,069	916	712	4,125	3,362
12 Paid up equity share capital (face value of Rs.2 each)				800	800
13 Other Equity				20,578	17,482
14 Earnings per share (of Rs.2 each): (not annualised for the quarter ended)					
(a) Basic (Rs.)*	2.54	2.22	1.64	9.61	7.75
(b) Diluted (Rs.)*	2.54	2.22	1.64	9.61	7.75

*The equity shares of the Company of Rs.10/- have been sub-divided into 5 equity shares of Rs.2/- each w.e.f. September 13, 2024, accordingly EPS has been restated for all the periods.



[Handwritten signature]

Notes:

- 1 The above statement of audited consolidated financial results of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company"), its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") and its associate, have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). These results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12 May 2025. The Statutory Auditors have expressed an unmodified opinion on the consolidated financial results.
- 2 The Consolidated figures for the quarter ended 31 March 2025 and quarter ended 31 March 2024 are the balancing figures between the audited consolidated figures in respect of the full financial year ended 31 March 2025 and 31 March 2024, respectively and the published year to date Consolidated figures up to third quarter 31 December 2024 and 31 December 2023, respectively which were subjected to a limited review.
- 3 The Board of Directors, at their meeting held on 28 June 2024, recommended for the sub-division of equity shares of the Company from existing face value of Rs. 10/- each to face value of Rs. 2/- each (i.e. split of 1 equity share of Rs. 10/- each into 5 equity shares of Rs. 2/- each), and the same has been approved by the shareholders in the Annual General Meeting of the Company held on 29 August 2024. The Company fixed the "record date" of 13 September 2024. Accordingly, equity shares of the Company of Rs. 10/- have been sub-divided into 5 equity shares of Rs. 2/- each w.e.f. 13 September 2024 and earnings per equity share has been restated for all the periods.
- 4 During the quarter, the Group has entered into a Hospital Operations and Management Agreements with entities engaged in medical services, thereby obtaining control over hospital operations and providing healthcare services using their assets. The transaction has been accounted for as a business combination under Ind AS 103-Business Combinations ("Ind AS 103"), with acquisition-related costs of Rs. 65 Mn included in other expenses.
- 5 During the quarter, the Group has entered into Operations and Management Agreements with entities in the healthcare sector to operate and manage their hospitals. The Group has also executed Call Option Agreements to acquire a majority equity stake in these entities at pre-agreed terms. The call options have been valued at Rs. 108 Mn and the gain has been recognized as an exceptional item.
- 6 During the year, Group has completed acquisition of 100% of the equity share capital of Chalasani Hospitals Private Limited (Queen's NRI Hospital) for a total cash consideration of Rs. 1,112 Mn, consisting of Rs. 277 Mn towards purchase of shares and Rs. 835 Mn towards purchase of hospital land and building. Consequently, Queen's NRI Hospital has become a wholly owned subsidiary. The transaction was accounted in accordance with Ind AS 103 and the purchase price allocation has been completed during the current quarter.
- 7 The Audited Consolidated Balance sheet and Audited Consolidated Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- 8 The Group operates in one single reportable business segment- "Medical and Healthcare services".
- 9 The above Audited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.



For and on behalf of the Board
Krishna Institute of Medical Sciences Limited





Dr. B. Bhaskara Rao
Managing Director
DIN: 00008985

Hyderabad
12 May 2025

Krishna Institute of Medical Sciences Limited
 Corporate Identity number : L55101TG1973PLC040558
 Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
 Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Audited Consolidated Balance Sheet as at 31 March 2025

(Rupees in millions)			
S.No	Particulars	As at 31 March 2025 (Audited)	As at 31 March 2024 (Audited)
A	ASSETS		
1	Non current Assets		
	Property, plant and equipment	21,988	17,301
	Capital work-in-progress	12,138	6,001
	Goodwill	3,386	3,080
	Other Intangible assets	677	646
	Right-of-use assets	7,434	3,312
	Investments accounted for using equity method	765	738
	Financial assets		
	(i) Investments	6	6
	(ii) Loans	55	260
	(iii) Other financial assets	601	349
	Deferred tax asset (net)	599	319
	Non-current tax assets (net)	438	455
	Other non-current assets	2,300	577
	Total Non current Assets - (1)	50,387	33,044
2	Current Assets		
	Inventories	640	494
	Financial assets		
	(i) Investments	220	829
	(ii) Trade receivables	3,954	2,944
	(iii) Cash and cash equivalents	560	469
	(iv) Bank balances other than (iii) above	237	21
	(v) Loans	477	-
	(vi) Other financial assets	508	358
	Other current assets	377	358
	Total Current Assets - (2)	6,973	5,473
3	Total Assets (3) = (1)+(2)	57,360	38,517
B	EQUITY AND LIABILITIES		
4	Equity		
	Equity share capital	800	800
	Other equity	20,578	17,482
	Equity attributable to Shareholders of the company - (4)	21,378	18,282
5	Non-controlling interests - (5)	2,810	2,649
6	Total Equity (6) = (4)+(5)	24,188	20,931
7	Non-current liabilities		
	Financial liabilities		
	(i) Borrowings	16,541	9,277
	(ii) Lease liabilities	6,331	2,988
	(iii) Other financial liabilities	778	65
	Provisions	335	274
	Other non-current liabilities	357	-
	Deferred tax liabilities (net)	468	463
	Total Non-current liabilities - (7)	24,810	13,067
8	Current liabilities		
	Financial liabilities		
	(i) Borrowings	2,519	1,186
	(ii) Lease liabilities	176	104
	(iii) Trade payables		
	(a) Total outstanding dues of micro enterprises and small enterprises; and	150	125
	(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	2,541	1,842
	(iv) Other financial liabilities	2,158	612
	Provisions	264	186
	Other current liabilities	538	464
	Current tax liabilities (Net)	16	-
	Total Current liabilities - (8)	8,362	4,519
9	Total Equity and Liabilities (9) = (6)+(7)+(8)	57,360	38,517





M. Arun

Krishna Institute of Medical Sciences Limited
 Corporate Identity number : L55101TG1973PLC040558
 Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
 Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Audited Consolidated Cash flows for the year ended 31 March 2025

(Rupees in millions)

Particulars	For the year ended	For the year ended
	31-Mar-25	31-Mar-24
	(Audited)	(Audited)
I. Cash flows from operating activities:		
Profit before tax for the year	5,581	4,595
Adjustments for operating activities:		
Depreciation and amortisation expenses	1,772	1,465
Finance costs	903	470
Profit on sale of property, plant and equipment (net)	(109)	(4)
Provision / (reversal) of expected credit loss for trade receivables (net of bad debts)	130	(14)
Interest income	(102)	(23)
Liabilities no longer required written back	(6)	(12)
Gain on mutual funds	(48)	(18)
Rental income	(7)	(5)
Gain on fair valuation of Call option (net)	(108)	-
Income on termination of lease	(5)	-
Share of loss of an associate	-	3
Operating cash flows before working capital changes	8,001	6,457
Adjustments for:		
(Increase)/Decrease		
- In Trade receivables	(934)	(403)
- in Inventories	(133)	(66)
- in Other financial assets and other assets	(322)	124
Increase in trade payables, other financial liabilities, provisions and other liabilities	620	502
Cash generated from operations	7,232	6,614
Income taxes paid, net of refunds	(1,414)	(1,402)
Net cash generated from operating activities (1)	5,818	5,212
II. Cash flows from investing activities		
Acquisition of property, plant and equipment and intangible assets	(10,089)	(6,473)
Proceeds from sale of property, plant and equipment	472	14
Investment in associate	(27)	(741)
Investment in equity shares	-	(6)
Acquisition of subsidiaries	(1,123)	-
Acquisition of business	(634)	-
Investment in mutual funds	(3,500)	(2,902)
Proceeds from sale of mutual funds	4,157	2,778
Loans given	(272)	(260)
Redemption of bank deposits (having original maturity of more than three months)	117	62
Investment in bank deposits (having original maturity of more than three months)	(349)	(14)
Rental income received	7	5
Interest received	79	11
Net cash used in investing activities (2)	(11,162)	(7,526)
III. Cash flows from financing activities		
Proceeds from long-term borrowings	8,487	4,593
Repayment of long-term borrowings	(837)	(177)
Proceeds from short-term borrowings (net)	288	714
Issue of preference shares to non controlling interest	64	-
Acquisition of non-controlling interest	(942)	(1,811)
Payment of principal of lease liability	(131)	(323)
Payment of interest on lease liability	(269)	(236)
Interest paid	(1,229)	(593)
Net cash flows generated from financing activities (3)	5,431	2,167
Net Increase/(decrease) in cash and cash equivalents (1+2+3)	87	(147)
Cash and cash equivalents acquired through business combination	4	-
Cash and cash equivalents at the beginning of the year	469	616
Cash and cash equivalents at the end of the year	560	469
Components of cash and cash equivalents		
Cash on hand	32	23
Balances with banks		
- On current accounts	461	288
- In deposit accounts (with original maturity of 3 months or less)	67	158
Total	560	469



M. S. Rao

Annexure-2

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No	Particulars	Description
1.	reason for change viz. appointment, re- appointment, resignation, removal, death or otherwise	Appointment of M/s. IKR & Associates, Company Secretaries, as the secretarial auditors of the Company to conduct secretarial audit of the Company for five consecutive years with effect from April 01, 2025 until March 31, 2030, subject to the approval of shareholders of the Company in the ensuing Annual General Meeting.
2.	date of appointment/re- appointment/ cessation (as applicable) & term of appointment/re- appointment	Appointed on May 12, 2025 for a term of Five Years i.e April 1 2025 until March 31 2030.
3.	brief profile (in case of appointment)	<p>The Firm, IKR & Associates, established in the year 2011 with a motive to provide consultancy services to the corporate world in the matter of Companies Act, SEBI Regulations, FEMA Regulations and other corporate laws.</p> <p>IKR & Associates specializes in solving the complexities of company law and company secretarial practice promptly and correctly and with an attention to deal and personal services.</p> <p>We are an established firm of Practicing Company Secretaries providing company secretarial services to both public and private companies. We are acknowledged experts in all areas of company secretarial practice and company law with a broad client base of exceptional depth and quality.</p> <p>IKR & Associates offers services in a wide range of sectors, primarily advising board members of their responsibilities and implementing board decisions. Properly managed secretarial services will keep you out of trouble at any International Business Registry and with third parties, such as banks, creditors, trustees, etc.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Annexure-3

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No	Particulars	Description
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of M/s. Sagar & Associates, Cost Accountants, as the cost auditors of the Company.
2.	date of appointment/re- appointment/cessation (as applicable) & term of appointment/re-appointment	Appointed on May 12, 2025 for a term of one year i.e April 1, 2025, to March 31, 2026.
3.	brief profile (in case of appointment)	<p>M/s. Sagar & Associates is a leading firm of Cost & Management Accountants having diversified activities in Cost and Management Accounting area.</p> <p>The firm consisting of qualified Cost Accountants and has undertaken many assignments in various industries. Our clients list includes leading and big companies with multiple locations and diversified product portfolio. We have very high exposure to ERP systems as the majority of our clients have SAP & ORACLE.</p>
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Annexure-4

Disclosure of information pursuant to Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sr. No	Particulars	Description
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment of Mrs. Y. Prameela Rani as an Independent Director for the further period of 5 years w.e.f 19.05.2025.
2.	date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	Re-appointed with effect from 19.05.2025 for a period of five years.
3.	brief profile (in case of appointment)	Mrs. Y. Prameela Rani is a MBA and CAIIB by qualification. She joined Andhra Bank in 1976 as a Probationary officer and served the bank for 36 years. Mrs. Y. Prameela Rani is a multi-talented successful banker possessing rich and varied experience in all facets of banking. She had exceptionally handled all her assignments such as Branch Head of critical branches, Zonal Manager of the largest zone and as General Manager (Large and Mid- Corporate Credit & MSME Credit) at corporate office before her superannuation. She attended several Senior Executive training programs in India and Abroad. She served as a member in the Indian Banks Association subcommittee on Joint lending Arrangement. She has the unique experience of overseeing the governance of diversified industrial companies as a member on their Board, while in service in the bank as Nominee Director and subsequently thereafter.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable